Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
83 hedge funds and large institutions have $128M invested in Aralez Pharmaceuticals Inc. in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 13 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 83 → 83 (0)
9% less capital invested
Capital invested by funds: $140M → $128M (-$11.9M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less call options, than puts
Call options by funds: $666K | Put options by funds: $920K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.27M |
| 2 |
AC
Armistice Capital
New York
|
+$3.49M |
| 3 |
BC
Broadfin Capital
New York
|
+$1.83M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$600K |
| 5 |
Morgan Stanley
New York
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOAM
Vertex One Asset Management
Vancouver,
British Columbia, Canada
|
-$1.57M |
| 2 |
KAM
Kavi Asset Management
New York
|
-$1.52M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.34M |
| 4 |
Millennium Management
New York
|
-$1.08M |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$634K |
ARLZ Hedge Fund Activity: Q4 2016 in Review
83 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q4 2016, worth a combined $128M — down 8.5% from $140M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ARLZ positions and 13 closed out — a net gain of 1 holder — while 29 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $4.27M. The largest seller was Vertex One Asset Management, exiting entirely with an estimated $1.57M sold.
- 83 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $128M of Aralez Pharmaceuticals Inc. stock for Q4 2016, down 8.5% quarter-over-quarter.
- 14 funds opened new Aralez Pharmaceuticals Inc. positions in Q4 2016 and 13 closed out, a net change of +1 holder.
- The largest Aralez Pharmaceuticals Inc. buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $4.27M added.
- The largest Aralez Pharmaceuticals Inc. seller in Q4 2016 was Vertex One Asset Management, an estimated $1.57M sold.
Based on aggregated 13F filings for Q4 2016.